Status:
COMPLETED
Active Drug Surveillance Program of Ferriprox Use
Lead Sponsor:
ApoPharma
Conditions:
Transfusional Iron Overload
Eligibility:
All Genders
Brief Summary
Observational, open label, prospective, multi-center, post-marketing drug surveillance program.
Detailed Description
A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients.
Eligibility Criteria
Inclusion
- Main
- Patients who started Ferriprox therapy less than one month or are to initiate Ferriprox therapy at the time of enrolment into the program.
- Main
Exclusion
- Patients treated with Ferriprox for more than one month prior to enrolment.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
294 Patients enrolled
Trial Details
Trial ID
NCT01838291
Start Date
June 1 2010
End Date
April 1 2013
Last Update
April 24 2013
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Thalassemia Center of North Cyprus Turkish Republic (KKTC)
Nicosia, Cyprus
2
Hematology Unit, Mansoura University Children Hospital
Al Mansurah, Egypt
3
Hematology Unit, El-Shatby Children Hospital, Alexandria University
Alexandria, Egypt
4
Hematology Unit, Assiut University Hospital
Asyut, Egypt